Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Maxcyte Inc (NQ: MXCT )

4.380 +0.190 (+4.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 517,016
Open 4.250
Bid (Size) 4.150 (1)
Ask (Size) 4.600 (1)
Prev. Close 4.190
Today's Range 4.200 - 4.465
52wk Range 3.360 - 7.760
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Looking Into MaxCyte's Return On Capital Employed
 
Via Benzinga
MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
31% Total Revenue Growth for Full Year 2022 including 26% Core Business Revenue Growth and $4.6 million in Program-related Revenue 
From MaxCyte, Inc
Via Globe NewsWire

Performance

YTD
-14.45%
-14.45%
1 Month
-5.40%
-5.40%
3 Month
-13.95%
-13.95%
6 Month
-23.16%
-23.16%
1 Year
-34.33%
-34.33%

More News

Read More
MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
From MaxCyte, Inc
Via Globe NewsWire
MaxCyte Earnings Perspective: Return On Capital Employed
Via Benzinga
MaxCyte Expects Q1 Sales To Beat Expectations, CFO Resigns
Via Benzinga
Earnings Scheduled For March 15, 2023
Via Benzinga
MaxCyte's Earnings: A Preview
Via Benzinga
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance
From MaxCyte, Inc
Via Globe NewsWire
7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023
Via InvestorPlace
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via Globe NewsWire
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
From MaxCyte, Inc
Via Globe NewsWire
7 Hot Stocks to Book Profits In Before 2023
Via InvestorPlace
MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
From MaxCyte, Inc
Via Globe NewsWire
MaxCyte Reports Third Quarter 2022 Financial Results
From MaxCyte, Inc
Via Globe NewsWire
Earnings Outlook For MaxCyte
Via Benzinga
MaxCyte to Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via Globe NewsWire
MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022
From MaxCyte, Inc
Via Globe NewsWire
MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders
Via Benzinga
MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program
From MaxCyte, Inc
Via Globe NewsWire
Recap: MaxCyte Q2 Earnings
Via Benzinga
A Preview Of MaxCyte's Earnings
Via Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Via Benzinga
Earnings Scheduled For May 9, 2022
Via Benzinga
MaxCyte's Return On Capital Employed Insights
Via Benzinga
Earnings Scheduled For March 22, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.